RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

Multi-kinase RET inhibitors, such as cabozantinib and RXDX-105, are active in lung cancer patients with RET fusions; however, the overall response rates to these two drugs are unsatisfactory compared to other targeted therapy paradigms. Moreover, these inhibitors may have different efficacies agains...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Dis Model Mech
Autores principales: Hayashi, Takuo, Odintsov, Igor, Smith, Roger S., Ishizawa, Kota, Liu, Allan J. W., Delasos, Lukas, Kurzatkowski, Christopher, Tai, Huichun, Gladstone, Eric, Vojnic, Morana, Kohsaka, Shinji, Suzawa, Ken, Liu, Zebing, Kunte, Siddharth, Mattar, Marissa S., Khodos, Inna, Davare, Monika A., Drilon, Alexander, Cheng, Emily, de Stanchina, Elisa, Ladanyi, Marc, Somwar, Romel
Formato: Artigo
Lenguaje:Inglês
Publicado: The Company of Biologists Ltd 2021
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7888717/
https://ncbi.nlm.nih.gov/pubmed/33318047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1242/dmm.047779
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares